The successful long-term treatment of age related erectile dysfunction with hSlo CDNA in rats in vivo

A. Melman, W. Zhao, Kelvin Davies, R. Bakal, G. J. Christ

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose: We have previously reported that 1 intracorporeal injection of 100 μg hSlo/pcDNA reversed the effect of aging on erectile function in a rat model in vivo for at least 2 months. We report our further investigations of the amplitude, duration and physiological relevance of this novel gene transfer approach. Materials and Methods: A total of 191 retired breeder Sprague-Dawley rats were given a single intracavernous injection of phosphate buffered saline, 1,000 μg pcDNA, or 10, 100 or 1,000 μg pcDNA/hSlo. The animals were studied 1 to 6 months after injection. The intracorporeal pressure (ICP) response to cavernous nerve stimulation and immunostaining as well as hematoxylin and eosin staining were done to evaluate effector nerve integrity and tissue histology, respectively. Results: Gene transfer prevented an age related decrease in resting ICP and a physiologically relevant, significant effect on normalizing erection in vivo, as determined by submaximal (0.5 mA) and maximal (4.0 mA) cavernous nerve stimulation. The effects were observed 1 month after transfection and sustained for 6 months at the 100 and 1,000 μg doses of pcDNA/hSlo (p < 0.026). Conclusions: The physiological manifestations of gene transfer were detected as an amelioration of the age related decrease in resting ICP, and parallel increase in the magnitude of the cavernous nerve stimulated an ICP response to a level at which visible erections were again observed in this rat model of aging in vivo.

Original languageEnglish (US)
Pages (from-to)285-290
Number of pages6
JournalJournal of Urology
Volume170
Issue number1
DOIs
StatePublished - Jul 1 2003

Fingerprint

Erectile Dysfunction
Pressure
Injections
Genes
Nerve Tissue
Therapeutics
Hematoxylin
Eosine Yellowish-(YS)
Transfection
Sprague Dawley Rats
Histology
Phosphates
Staining and Labeling

Keywords

  • Gene therapy
  • Impotence
  • Muscle, smooth
  • Penis
  • Rats, Sprague-Dawley

ASJC Scopus subject areas

  • Urology

Cite this

The successful long-term treatment of age related erectile dysfunction with hSlo CDNA in rats in vivo. / Melman, A.; Zhao, W.; Davies, Kelvin; Bakal, R.; Christ, G. J.

In: Journal of Urology, Vol. 170, No. 1, 01.07.2003, p. 285-290.

Research output: Contribution to journalArticle

Melman, A. ; Zhao, W. ; Davies, Kelvin ; Bakal, R. ; Christ, G. J. / The successful long-term treatment of age related erectile dysfunction with hSlo CDNA in rats in vivo. In: Journal of Urology. 2003 ; Vol. 170, No. 1. pp. 285-290.
@article{68933359ea1b4512a3610d8946f6caf5,
title = "The successful long-term treatment of age related erectile dysfunction with hSlo CDNA in rats in vivo",
abstract = "Purpose: We have previously reported that 1 intracorporeal injection of 100 μg hSlo/pcDNA reversed the effect of aging on erectile function in a rat model in vivo for at least 2 months. We report our further investigations of the amplitude, duration and physiological relevance of this novel gene transfer approach. Materials and Methods: A total of 191 retired breeder Sprague-Dawley rats were given a single intracavernous injection of phosphate buffered saline, 1,000 μg pcDNA, or 10, 100 or 1,000 μg pcDNA/hSlo. The animals were studied 1 to 6 months after injection. The intracorporeal pressure (ICP) response to cavernous nerve stimulation and immunostaining as well as hematoxylin and eosin staining were done to evaluate effector nerve integrity and tissue histology, respectively. Results: Gene transfer prevented an age related decrease in resting ICP and a physiologically relevant, significant effect on normalizing erection in vivo, as determined by submaximal (0.5 mA) and maximal (4.0 mA) cavernous nerve stimulation. The effects were observed 1 month after transfection and sustained for 6 months at the 100 and 1,000 μg doses of pcDNA/hSlo (p < 0.026). Conclusions: The physiological manifestations of gene transfer were detected as an amelioration of the age related decrease in resting ICP, and parallel increase in the magnitude of the cavernous nerve stimulated an ICP response to a level at which visible erections were again observed in this rat model of aging in vivo.",
keywords = "Gene therapy, Impotence, Muscle, smooth, Penis, Rats, Sprague-Dawley",
author = "A. Melman and W. Zhao and Kelvin Davies and R. Bakal and Christ, {G. J.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1097/01.ju.0000063375.12512.6e",
language = "English (US)",
volume = "170",
pages = "285--290",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The successful long-term treatment of age related erectile dysfunction with hSlo CDNA in rats in vivo

AU - Melman, A.

AU - Zhao, W.

AU - Davies, Kelvin

AU - Bakal, R.

AU - Christ, G. J.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Purpose: We have previously reported that 1 intracorporeal injection of 100 μg hSlo/pcDNA reversed the effect of aging on erectile function in a rat model in vivo for at least 2 months. We report our further investigations of the amplitude, duration and physiological relevance of this novel gene transfer approach. Materials and Methods: A total of 191 retired breeder Sprague-Dawley rats were given a single intracavernous injection of phosphate buffered saline, 1,000 μg pcDNA, or 10, 100 or 1,000 μg pcDNA/hSlo. The animals were studied 1 to 6 months after injection. The intracorporeal pressure (ICP) response to cavernous nerve stimulation and immunostaining as well as hematoxylin and eosin staining were done to evaluate effector nerve integrity and tissue histology, respectively. Results: Gene transfer prevented an age related decrease in resting ICP and a physiologically relevant, significant effect on normalizing erection in vivo, as determined by submaximal (0.5 mA) and maximal (4.0 mA) cavernous nerve stimulation. The effects were observed 1 month after transfection and sustained for 6 months at the 100 and 1,000 μg doses of pcDNA/hSlo (p < 0.026). Conclusions: The physiological manifestations of gene transfer were detected as an amelioration of the age related decrease in resting ICP, and parallel increase in the magnitude of the cavernous nerve stimulated an ICP response to a level at which visible erections were again observed in this rat model of aging in vivo.

AB - Purpose: We have previously reported that 1 intracorporeal injection of 100 μg hSlo/pcDNA reversed the effect of aging on erectile function in a rat model in vivo for at least 2 months. We report our further investigations of the amplitude, duration and physiological relevance of this novel gene transfer approach. Materials and Methods: A total of 191 retired breeder Sprague-Dawley rats were given a single intracavernous injection of phosphate buffered saline, 1,000 μg pcDNA, or 10, 100 or 1,000 μg pcDNA/hSlo. The animals were studied 1 to 6 months after injection. The intracorporeal pressure (ICP) response to cavernous nerve stimulation and immunostaining as well as hematoxylin and eosin staining were done to evaluate effector nerve integrity and tissue histology, respectively. Results: Gene transfer prevented an age related decrease in resting ICP and a physiologically relevant, significant effect on normalizing erection in vivo, as determined by submaximal (0.5 mA) and maximal (4.0 mA) cavernous nerve stimulation. The effects were observed 1 month after transfection and sustained for 6 months at the 100 and 1,000 μg doses of pcDNA/hSlo (p < 0.026). Conclusions: The physiological manifestations of gene transfer were detected as an amelioration of the age related decrease in resting ICP, and parallel increase in the magnitude of the cavernous nerve stimulated an ICP response to a level at which visible erections were again observed in this rat model of aging in vivo.

KW - Gene therapy

KW - Impotence

KW - Muscle, smooth

KW - Penis

KW - Rats, Sprague-Dawley

UR - http://www.scopus.com/inward/record.url?scp=0038340638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038340638&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000063375.12512.6e

DO - 10.1097/01.ju.0000063375.12512.6e

M3 - Article

C2 - 12796707

AN - SCOPUS:0038340638

VL - 170

SP - 285

EP - 290

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -